Pfizer's Ibrance Secures First FDA Expansion in Seven Years with Maintenance Win in HR+/HER2+ Metastatic Breast Cancer
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved Pfizer's blockbuster CDK4/6 inhibitor, Ibrance (palbociclib), in combination with anti-HER2 therapy and endocrine therapy, as a maintenance treatment for adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer.
This approval marks a major milestone: Ibrance is now the first and only CDK4/6 inhibitor approved to treat patients with HR+ metastatic breast cancer regardless of their HER2 status, bridging a major therapeutic gap in "double-positive" (HR+/HER2+) breast cancer.
Clinical Data Supporting the Approval
The FDA's decision is supported by results from the Phase 3 PATINA trial, which evaluated Ibrance in combination with standard frontline maintenance therapy—consisting of Roche’s Herceptin (trastuzumab), with or without Perjeta (pertuzumab), and endocrine therapy—following first-line induction treatment. Key findings from the trial include:
- PFS Improvement: The addition of Ibrance to the standard maintenance regimen reduced the risk of disease progression or death by 24% (HR = 0.76).
- Survival Extension: The palbociclib-based regimen extended the median progression-free survival (PFS) by 15.2 months, reaching 44.3 months compared to 29.1 months in the control group.
Reversing a Losing Streak in a Crowded Class
This approval is Pfizer's first label expansion for Ibrance in seven years and represents a critical victory. While Ibrance was the first CDK4/6 inhibitor to reach the market in 2015, its sales have steadily declined from a peak of $5.4 billion in 2020 to $4.1 billion in 2025. It has recently fallen behind class competitors Eli Lilly’s Verzenio (which generated $5.7 billion in 2025) and Novartis’ Kisqali ($4.8 billion in 2025).
The PATINA results provide a much-needed lift for Ibrance after a series of late-stage failures, including the Phase 3 PALOMA-2 trial in first-line HR+/HER2- disease and two post-surgery adjuvant trials.
"With today’s FDA approval, Ibrance becomes the first and only CDK4/6 inhibitor indicated for patients with HR+ metastatic breast cancer regardless of HER2 status, extending its impact to patients who continue to face challenges with treatment resistance." — Aamir Malik, Pfizer U.S. Commercial Officer, June 2026
"Paving the way for the expansion were results from the phase 3 Patina study, which showed that Ibrance added to standard of care reduced the risk of disease progression or death by 24% in the specific patient population following induction treatment, Pfizer said in a Wednesday press release. The Ibrance combo also extended the median progression-free survival time of patients by 15.2 months to 44.3 months." — Fierce Pharma, June 2026